Choose HA†
Prescribing Information   |  OAKneePainRelief.com
7.2.3-header-AdobeStock_103718357

Confidently choose DUROLANE for your patients.

Get DUROLANE for Your Patients

Proven in more clinical studies than any other single-injection hyaluronic acid knee therapy, DUROLANE has been shown to be safe and effective.

See additional DUROLANE Resources

During the DUROLANE pivotal trial:13

  • No serious adverse events were considered related to DUROLANE treatment.13
  • The most common adverse events were arthralgia (8.6%), injection site pain (2.3%), and joint swelling (1.7%).13

DUROLANE is safe for repeated courses of therapy. Repeat administration of a course of DUROLANE therapy does not increase the incidence of adverse events.11,13

Choose DUROLANE for Longer-lasting Results

  • Total joint residence time of approximately 150 days based on a half-life of 30 days.48
  • A half-life of 30 days (approximately 4 weeks) in the knee joint in a single-injection treatment regimen35
  • The longest reported half-life of any HA32-35

‡The clinical relevance of this information has not been determined.

Get your DUROLANE rebate today Get Rebate

DUROLANE, GELSYN-3 and SUPARTZ FX are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g., acetaminophen. Risks include general knee pain and pain at the injection site.

View Use and Important Safety Information at: DUROLANE.com, GELSYN3.com, and SUPARTZFX.COM

Summary of Indications for Use:
DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

DUROLANE has not been tested in pregnant or lactating women, or children.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.